Shares of Sun Pharmaceutical Industries rose more than 7% on Monday after India's largest drugmaker announced it would acquire New Jersey-based Organon & Co in an all-cash deal valued at $11.75 billion, including debt.
The acquisition, which is expected to close by the end of 2026, will give Sun Pharma access to Organon's portfolio of women's health products and biosimilars. Organon, spun off from Merck & Co in 2021, had revenues of $6.3 billion in 2025.
Sun Pharma said the deal will be funded through a combination of cash on hand and debt financing. The company's shares closed at 1,234.50 rupees on the National Stock Exchange, up 7.2% from the previous close.
